BioSpace News Archive

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast a presentation from the UBS Global Healthcare Conference.

IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023

Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health

Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral presentation Early dose escalation study will highlight antigen-specific CD8+ T cell data, anti-tumor activity and overall tolerability of HB-201 and HB-201/HB-202

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization integrating US and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, and Quality Assurance, is pleased to announce the hiring of Fernando Aguel as Vice President, Heart Failure & Circulatory Support Regulatory Affairs.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2021 on Wednesday, May 26, 2021

Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Soligenix, Inc. (Nasdaq: SNGX) announced today that the Japan Patent Office has allowed the patent application titled “Systems and Methods for Producing Synthetic Hypericin”.